SGN‐CD33, a CD33-directed antibody conjugated to two molecules of a pyrrolobenzodiazepine dimer, has been evaluated as monotherapy in patients with CD33-positive AML with CR + CRi rates up to 60% in treatment naïve patients and in combination with hypomethylating agents [182, 183]. Here, CD33 is linked to acute myeloid leukemia.